Characterizing the outcomes of metastatic papillary renal cell carcinoma

Abstract

Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.

We show that pRCC patients have significantly worse outcomes than ccRCC patients, that no targeted therapy to date is superior to one-another, and that metastatic type I pRCC is far less common than type II but may convey a better survival outcome. Furthermore, this is the first study to demonstrate that the IMDC prognostic model effectively stratifies pRCC patients into good, intermediate, or poor-risk groups, providing physicians with more evidence to inform patients of their expected prognosis.

http://ift.tt/2oNWMng

Characterizing the outcomes of metastatic papillary renal cell carcinoma

Abstract

Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.

We show that pRCC patients have significantly worse outcomes than ccRCC patients, that no targeted therapy to date is superior to one-another, and that metastatic type I pRCC is far less common than type II but may convey a better survival outcome. Furthermore, this is the first study to demonstrate that the IMDC prognostic model effectively stratifies pRCC patients into good, intermediate, or poor-risk groups, providing physicians with more evidence to inform patients of their expected prognosis.

from Cancer via ola Kala on Inoreader http://ift.tt/2oNWMng
via IFTTT

Effects of BEAT Cancer randomized physical activity trial on subjective memory impairments in breast cancer survivors

from Cancer via ola Kala on Inoreader http://ift.tt/2oEAWCi
via IFTTT

Effects of BEAT Cancer randomized physical activity trial on subjective memory impairments in breast cancer survivors

http://ift.tt/2oEAWCi

Intraplacental Choriocarcinoma: Rare or Underdiagnosed? Report of 2 Cases Diagnosed after an Incomplete Miscarriage and a Preterm Spontaneous Vaginal Delivery

Intraplacental choriocarcinoma is a rare malignant tumor diagnosed after an abortion, an ectopic pregnancy, or a term or preterm pregnancy or following the diagnosis of a hydatidiform mole. During pregnancy, it may be more common than reported, as most patients are asymptomatic and placental choriocarcinomas are usually inconspicuous macroscopically and are often mistaken for an infarct. Based upon a case study methodology, we describe 2 cases of intraplacental choriocarcinoma: the first case was identified in the product of a uterine curettage following an incomplete miscarriage and the second in one of the placentas of a bichorionic twin pregnancy. Maternal investigation did not reveal evidence of metastatic disease and neither did the infants' one in the second case. The two cases underwent maternal surveillance with serum hCG and remained disease-free until the present. In conclusion, intraplacental choriocarcinoma is easily underdiagnosed but with current treatment, even in the presence of metastasis, the prognosis is excellent. A routine microscopic examination of all the placentas and products of miscarriage can increase the real incidence of this entity and consequently improve its management.

http://ift.tt/2oDgdP3

Hemoptysis as primary manifestation in three women with choriocarcinoma with pulmonary metastasis: a case series

Gestational choriocarcinoma is the most common gestational trophoblastic neoplasia; it is often secondary to hydatidiform mole, as well as to abortion, ectopic pregnancy, premature delivery, or term delivery. ...

http://ift.tt/2nQV3yr